IP Library Granted Patent US 7,803,768
Granted Patent B2
US 7,803,768 · App. 11/884,881 · Granted Sep 28, 2010

Method for treatment of hyperglycemia in a subject in need thereof

Assignees: Kyoto University; Daiichi Sankyo Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,768
App. No.
11/884,881
Granted
Sep 28, 2010
Kind
B2
Abstract

A pharmaceutical for promoting neogenesis or regeneration of pancreatic β cells which produces and secretes insulin and for promoting insulin production in β cells, comprising ghrelin or a derivative thereof as an effective component.

Claims (12)

1. A method for suppression or treatment of hyperglycemia, which comprises administering an effective amount of a peptide compound or a pharmaceutically acceptable salt thereof, to a patient in need thereof,

wherein the peptide compound is growth hormone-releasing peptide-2 (GHRP-2) or a peptide having an amino acid sequence of any one of SEQ ID NOs: 1 to 21 wherein the 3rd amino acid residue from an amino terminus is a modified amino acid residue wherein a side chain of the amino acid residue is acylated by a fatty acid.

2. The method according to claim 1 , wherein hyperglycemia is caused by no insulin secretion or very low insulin secretion due to debility or death of pancreatic β cells, or caused by decreased insulin secretion in pancreatic β cells.

3. The method according to any one of claims 1 and 2 , wherein hyperglycemia has a value (ΔIRI/ΔBG) of the difference in values of blood insulin 30 minutes after the load and before the load (ΔIRI) divided by the difference in sugar blood values 30 minutes after the load and before the load (ΔBG) of not more than 0.4.

4. The method according to claim 1 , wherein the peptide is selected from the group consisting of (1) a peptide having an amino acid sequence of SEQ ID NO: 1 wherein the 3rd amino acid residue from an amino terminus is a modified amino acid residue having a fatty acid introduced to a side chain of the amino acid residue and (2) GHRP-2.

5. The method according to claim 4 , wherein the peptide has an amino acid sequence of SEQ ID NO: 1 and a serine residue in the 3rd position from an amino terminus is a modified amino acid residue having a fatty acid introduced to a hydroxyl group of a side chain of the residue.

6. The method according to claim 5 , wherein the peptide has an amino acid sequence of SEQ ID NO: 1 and a hydroxyl group of a side chain of a serine residue in the 3rd position from an amino terminus is acylated by an n-octanoyl group.

7. The method according to claim 4 , wherein the peptide is GHRP-2.

8. The method according to claim 1 , wherein neogenesis or regeneration of pancreatic β cells is promoted.

9. The method according to claim 1 , wherein insulin production in pancreatic β cells is promoted.

10. The method according to claim 1 , wherein debility, death or wearing out of pancreatic β cells is suppressed.

11. The method according to claim 1 , wherein the peptide compound is GHRP-2 or a peptide having an amino acid sequence of any one of SEQ ID NOs: 1 to 9 and 21 wherein the 3rd amino acid residue from an amino terminus is a modified amino acid residue wherein a side chain of the amino acid residue is acylated by a fatty acid.

Assignments (4)
NUNC PRO TUNC ASSIGNMENT Recorded Apr 12, 2023
From: KYOTO UNIVERSITY
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 063296/0927 →
MERGER Recorded Jul 13, 2010
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024674/0910 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2007
From: KODA, SHUICHI; WAKABAYASHI, NAOMI
To: KYOTO UNIVERSITY; ASUBIO PHARMA CO., LTD.
Reel/Frame 024443/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2007
From: KANGAWA, KENJI; AKAMIZU, TAKASHI; IRAKO, TAIGA
To: KYOTO UNIVERSITY; ASUBIO PHARMA CO., LTD.
Reel/Frame 024443/0527 →
Priority Claims (2)
JP 2005-046562 · Feb 23, 2005 · national
JP 2006-003219 · Jan 11, 2006 · national
Continuity (1)
Related Publication 20090143284A1 · Jun 4, 2009